Get the Stockscreener App
4.68
6.40%
-0.32
After Hours:
4.75
0.07
+1.50%
Achieve Life Sciences Inc stock is traded at $4.68, with a volume of 1.25M.
It is down -6.40% in the last 24 hours and up +55.48% over the past month.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
See More
Previous Close:
$5.00
Open:
$5
24h Volume:
1.25M
Relative Volume:
0.90
Market Cap:
$239.17M
Revenue:
-
Net Income/Loss:
$-32.94M
P/E Ratio:
-4.2162
EPS:
-1.11
Net Cash Flow:
$-24.95M
1W Performance:
-6.40%
1M Performance:
+55.48%
6M Performance:
+98.31%
1Y Performance:
-0.64%
1-Day Range:
$4.66
$5.07
1-Week Range:
$4.66
$5.78
52-Week Range:
$1.84
$5.78
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.68 | 255.52M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
Achieve Life Sciences Inc Stock (ACHV) Latest News
Is Achieve Life Sciences Inc. still worth holding after the dipQuarterly Performance Summary & Weekly Breakout Stock Alerts - newser.com
Will Achieve Life Sciences Inc. (SP4P) stock benefit from commodity supercycleQuarterly Profit Review & Low Drawdown Momentum Trade Ideas - newser.com
How Achieve Life Sciences Inc. (SP4P) stock reacts to monetary easingPrice Action & Verified High Yield Trade Plans - newser.com
Can Achieve Life Sciences Inc. stock deliver strong Q4 earningsBuy Signal & Accurate Buy Signal Notifications - newser.com
Will Achieve Life Sciences Inc. stock continue dividend increasesSwing Trade & Smart Investment Allocation Tips - newser.com
What momentum shifts mean for Achieve Life Sciences Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Using R and stats models for Achieve Life Sciences Inc. forecasting2025 Investor Takeaways & Weekly High Momentum Picks - newser.com
Ranking Achieve Life Sciences Inc. among high performing stocks via toolsM&A Rumor & AI Forecasted Stock Moves - newser.com
Advanced analytics toolkit walkthrough for Achieve Life Sciences Inc.2025 Big Picture & Fast Gaining Stock Reports - newser.com
Will Achieve Life Sciences Inc. stock deliver long term returnsMarket Risk Summary & Capital Protection Trade Alerts - newser.com
Is Achieve Life Sciences Inc. (SP4P) stock a momentum leaderJuly 2025 Technicals & Fast Moving Stock Watchlists - newser.com
Is Achieve Life Sciences Inc. stock supported by strong cash flowsJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - newser.com
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):